Mexico.- The Federal Commission for Protection against Sanitary Risks (Cofepris), warned about the filing of 10 batches of the treatment oncology Opdivo (nivolumab) and a lot of Meropenemantibiotic for the exclusive use of the Health sector.
Through a statement, Cofepris explained that in the case of Opdivo (nivolumab)the counterfeits were detected in a 100mg/10mL solution presentation, manufactured by the pharmaceutical company Bristol Myers Squibb of Mexico and indicated to treat carcinomas, melanomas, lung cancer and Hodgkin’s lymphoma.
These 10 counterfeit lots can be identified with the following series; AAQ6790, BBB3855, ADE3101, BBS2497, AAX7296, ABG4099, BBS2500, ABL4615, ABW6875, AA23012.
The health authority explained that these batches have various irregularities, such as; “Opaque and rigid security seals, legends in English, no display of sanitary registration number or brand logo on secondary packaging, primary packaging with a dark gray and/or white removable lid with a blue cap and identification lines on the front of the container. There are differences between the fake batches, so each one registers different anomalies.”
As for the antibiotic to treat infections Meropenem, it was also identified as false. This medicine is manufactured by Laboratorios Pisa SA de CV, it is for the exclusive use of the Health sector; however, batch K17A812 was not produced by the company.
Cofepris reported that this alert is intended so that patients, medical personnel or distributors can recognize fake products to prevent damage to health by avoiding their consumption.
In such a situation, the health authority requests those who have these medications to verify them, and in case they are counterfeit because they have any of the aforementioned characteristics, to suspend their consumption immediately.
He also warned about the risk that exists when I purchased supposed drugs for consumption by unauthorized providers, and reiterated that exclusive products from the Health Sector should not be marketed.
Read more: Mexico prepares for the arrival of a new HIV treatment
“By not knowing the origin of these products, their components, manufacturing conditions and storage methods, their consumption represents a health risk. In the event of having consumed the counterfeit product and presenting any adverse reaction or discomfort, Cofepris makes available the report email [email protected].”Cofepris concluded in the statement.
#Cofepris #alert #falsification #Optdivo #oncology #drug #antibiotic #Meropenem